Healthcare Services

Pars Planitis Treatment Market Outlook 2026–2030: Key Business Drivers and Trends

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pars planitis treatment market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Pars Planitis Treatment Market expected to grow between 2026 and 2030?

The pars planitis treatment market has demonstrated strong expansion in recent years. This market is forecast to grow from $683.54 billion in 2025 to $737.86 billion by 2026, advancing at a compound annual growth rate (CAGR) of 7.9%. The historical period’s growth is attributable to an improved understanding of uveitis pathophysiology, the availability of corticosteroid-based therapies, the expansion of ophthalmology specialty clinics, increasing diagnostic imaging utilization, and growing clinical awareness of pars planitis.

The pars planitis treatment market is projected to experience significant expansion in the coming years. It is anticipated to reach $989.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This growth during the forecast period is attributable to the increasing adoption of personalized ophthalmic treatments, rising demand for long-term inflammation control, the expansion of biologic drug pipelines, a growing focus on vision preservation strategies, and increasing investment in advanced ophthalmic diagnostics. Major trends expected in this period include the increasing use of immunomodulatory therapies, rising adoption of biologic agents, a growing preference for targeted anti-inflammatory treatments, the expansion of advanced ocular surgical techniques, and an enhanced focus on early diagnosis and disease monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24649&type=smp

Which Drivers Are Influencing Market Acceleration In The Pars Planitis Treatment Market?

The growing occurrence of pars planitis is anticipated to drive expansion in the pars planitis treatment market moving forward. Pars planitis is characterized as an idiopathic type of intermediate uveitis, predominantly leading to inflammation within the vitreous and peripheral retina, usually impacting people between the ages of 15 and 40. This rising prevalence stems from increased awareness and enhanced diagnostic methods, with sophisticated imaging tools facilitating earlier and more precise identification. Treatments for pars planitis aid in managing the condition by diminishing inflammation in the eye, which is crucial for maintaining vision and averting further complications. These therapies improve patient care through targeted options like corticosteroids and immunosuppressants, contributing to better long-term eye health and an improved quality of life. For example, a case report from February 2025, published by the US-based medical journal Mega Journal of Case Reports, indicated that intermediate uveitis has an incidence rate of 1.4 to 2 cases per 100,000 individuals, with pars planitis, the idiopathic variant, making up 70% of these occurrences. Consequently, the escalating incidence of pars planitis is propelling expansion within the pars planitis treatment market.

What Leading Segments Are Studied In The Pars Planitis Treatment Market?

The pars planitis treatment market covered in this report is segmented –

1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments

2) By Diagnosis: Blood Tests, Fundus Examination And Optical Coherence Tomography, Magnetic Resonance Imaging (MRI), Other Diagnosis

3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids

2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery

4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy

5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents

6) By Other Treatments: Antibiotics, Antivirals, Laser therapy

What Trends Are Expected To Impact The Competitive Landscape Of The Pars Planitis Treatment Market?

Major companies engaged in the pars planitis treatment market are concentrating on developing novel solutions, such as bispecific antibodies, with the aim of enhancing immune modulation, reducing inflammation in the eye, and minimizing systemic adverse effects. These bispecific antibodies are engineered proteins crafted to simultaneously bind to two distinct antigens or targets, thereby providing more precise and effective treatment while limiting side effects. For instance, in October 2023, Genentech Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for Vabysmo (faricimab-svoa) for the management of retinal vein occlusion (RVO), in addition to its existing indications for age-related macular degeneration and diabetic macular edema. Vabysmo holds the distinction of being the first bispecific antibody for ophthalmic use that targets both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), effectively addressing inflammation and vascular leakage concurrently. This innovative therapeutic approach is currently being explored for its application in intermediate uveitis, including pars planitis, conditions where chronic inflammation in the retinal periphery demands durable and targeted intervention.

Which Major Industry Participants Are Leading The Pars Planitis Treatment Market Growth?

Major companies operating in the pars planitis treatment market are Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd, Quantum Cryogenics Ltd, Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Clearside Biomedical Inc, Roche Holding AG, Pfizer Inc, Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, UCB SA, Bausch Health Companies Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Pars Planitis Treatment Market?

North America was the largest region in the pars planitis treatment market in 2025. The regions covered in the pars planitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pars Planitis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24649&type=smp

Browse Through More Reports Similar to the Global Pars Planitis Treatment Market 2026, By The Business Research Company

Agricultural Wastewater Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/agricultural-wastewater-treatment-global-market-report

Non Invasive Aesthetic Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-invasive-aesthetic-treatment-global-market-report

Nasal Polyps Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nasal-polyps-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795